Document Detail


Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy?
MedLine Citation:
PMID:  10458348     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: We assessed the need for transurethral biopsy of the bladder at the 3-month evaluation in patients who have received intravesical bacillus Calmette-Guerin (BCG). MATERIALS AND METHODS: A total of 81 patients collectively received 83, 6-week courses of BCG between 1995 and 1997, and underwent transurethral bladder biopsies 3 months after initiation of immunotherapy. The pretreatment and posttreatment bladder biopsy results, urinary cytology and posttreatment cystoscopic findings were correlated. RESULTS: Transitional cell carcinoma was demonstrated in 5 of 11 patients with erythematous bladder mucosa and a positive cytology compared to none of 37 with an erythematous lesion and a negative cytology. Of 12 patients with a papillary lesion on cystoscopy and a positive biopsy 10 had a negative cytology, and only 1 of 13 patients with a negative cystoscopy had a positive biopsy. CONCLUSIONS: Bladder biopsy is not necessary in patients 3 months after receiving BCG who have a normal office cystoscopy or an erythematous bladder and normal urine cytology.
Authors:
G Dalbagni; T Rechtschaffen; H W Herr
Related Documents :
19519608 - Extra-anogenital bilharziasis cutanea tarda revisited.
15164258 - Tuberculous vertebral osteomyelitis in the new millennium: still a diagnostic and thera...
9093588 - 'localized amyloidosis': 123i-labelled sap component scintigraphy and labial salivary g...
1944988 - Breast-conserving therapy for invasive carcinoma: diagnosis of local recurrence.
24620948 - Erythrocytic phosphatidylserine exposure and hemostatic alterations in β-thalassemia i...
1894168 - Manometric characterization of rectal dysfunction following radical hysterectomy.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of urology     Volume:  162     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  1999 Sep 
Date Detail:
Created Date:  1999-09-23     Completed Date:  1999-09-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  708-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / therapeutic use*
Adult
Aged
Aged, 80 and over
BCG Vaccine / therapeutic use*
Biopsy / statistics & numerical data*
Carcinoma, Transitional Cell / drug therapy*,  pathology*
Female
Humans
Male
Middle Aged
Time Factors
Urethra
Urinary Bladder Neoplasms / drug therapy*,  pathology*
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/BCG Vaccine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recurrence and progression in low grade papillary urothelial tumors.
Next Document:  A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carci...